Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.
2.

Why we should not skip aspirin in cardiovascular prevention.

Schrör K.

Hamostaseologie. 2015 Apr 20;35(20150420). [Epub ahead of print]

PMID:
25891122
3.

Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation.

Arnao V, Agnelli G, Paciaroni M.

Intern Emerg Med. 2015 Aug;10(5):555-60. doi: 10.1007/s11739-015-1226-4. Epub 2015 Apr 11.

PMID:
25862436
4.

The spectrum of thrombin in acute coronary syndromes.

Giri S, Jennings LK.

Thromb Res. 2015 May;135(5):782-7. doi: 10.1016/j.thromres.2015.02.013. Epub 2015 Feb 21. Review.

PMID:
25764910
5.

New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents.

Rahman A, Latona J.

Aust Fam Physician. 2014 Dec;43(12):861-6.

PMID:
25705736
6.

Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?

Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG.

Am Heart J. 2014 Nov;168(5):611-21. doi: 10.1016/j.ahj.2014.06.014. Epub 2014 Jun 26. Review.

PMID:
25440788
7.

[Antithrombotic therapy and atrial fibrillation. Dual or triple therapy after acute coronary syndrome and stent?].

Zeymer U, Zahn R.

Herz. 2014 Nov;39(7):814-8. doi: 10.1007/s00059-014-4164-4. German.

PMID:
25336242
8.

Dual antiplatelet therapy in the anticoagulated patient undergoing percutaneous coronary intervention risks, benefits, and unanswered questions.

Bennaghmouch N, Dewilde WJ, Ten Berg JM.

Curr Cardiol Rep. 2014 Dec;16(12):548. doi: 10.1007/s11886-014-0548-6. Review.

PMID:
25326731
9.

Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.

Thompson PL, Verheugt FW.

Clin Ther. 2014 Sep 1;36(9):1176-81. doi: 10.1016/j.clinthera.2014.08.010.

PMID:
25234549
10.

The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties.

Iung B, Rodés-Cabau J.

Eur Heart J. 2014 Nov 7;35(42):2942-9. doi: 10.1093/eurheartj/ehu365. Epub 2014 Sep 8. Review.

PMID:
25205532
11.

Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.

Trujillo T, Dobesh PP.

Drugs. 2014 Sep;74(14):1587-603. doi: 10.1007/s40265-014-0278-5. Review. Erratum in: Drugs. 2014 Oct;74(15):1837.

12.

[Historical and future perspective of antithrombotic agents].

Goto S.

Nihon Rinsho. 2014 Jul;72(7):1193-7. Review. Japanese.

PMID:
25163307
13.

The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome.

Camuglia AC, Waddell-Smith KE, Hammett CJ, Aylward PE.

Curr Med Res Opin. 2014 Nov;30(11):2151-67. doi: 10.1185/03007995.2014.949647. Epub 2014 Aug 20. Review.

PMID:
25140867
14.

Antithrombotics in atrial fibrillation and coronary disease.

Velagapudi P, Turagam MK, Agrawal H, Mittal M, Kocheril AG, Aggarwal K.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):977-86. doi: 10.1586/14779072.2014.937427. Review.

PMID:
25046150
15.

Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.

Weitz JI.

Thromb Haemost. 2014 Nov;112(5):924-31. doi: 10.1160/TH14-03-0265. Epub 2014 Jul 17. Review.

PMID:
25030773
16.

Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.

Turpie AG.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):963-76. doi: 10.1586/14779072.2014.938055. Epub 2014 Jul 12. Review.

PMID:
25017622
17.

The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Cohen M, Iyer D.

Cardiovasc Ther. 2014 Oct;32(5):224-32. doi: 10.1111/1755-5922.12083. Review.

18.

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.

Shivu GN, Ossei-Gerning N.

Vasc Health Risk Manag. 2014 May 12;9:291-302. doi: 10.2147/VHRM.S59420. eCollection 2014. Review.

19.

Direct oral anticoagulants in acute coronary syndrome.

Ahrens I, Bode C.

Semin Hematol. 2014 Apr;51(2):147-51. doi: 10.1053/j.seminhematol.2014.03.004. Epub 2014 Mar 29.

PMID:
24861799
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk